Thus, EZH2 inhibition does not change SOX2 expression in SS18-SSX positive synovial sarcoma cell lines, but is able to reverse some synovial sarcoma-specific gene expression, at least ATF3, and others less consistently across models. Here, SOX2 is linked to synovial sarcoma.